p.103 抽出テキスト

823. Arima H, Chalmers J, Woodward M, Anderson C, Rodgers A, Davis S, et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens 2006;24:1201–8. https://doi.org/10.1097/01.hjh. 0000226212.34055.86 824. Kitagawa K, Yamamoto Y, Arima H, Maeda T, Sunami N, Kanzawa T, et al. Effect of standard vs intensive blood pressure control on the risk of recurrent stroke: a randomized clinical trial and meta-analysis. JAMA Neurol 2019;76:1309–18. https://doi.org/10. 1001/jamaneurol.2019.2167 825. Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R, Pratt N, et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet 2019;394: 1816–26. https://doi.org/10.1016/s0140-6736(19)32317-7 826. Wang WT, You LK, Chiang CE, Sung S-H, Chuang S-Y, Cheng H-M, et al. Comparative effectiveness of blood pressure-lowering drugs in patients who have already suffered from stroke: traditional and Bayesian network meta-analysis of randomized trials. Medicine (Baltimore) 2016;95:e3302. https://doi.org/10.1097/md.0000000000003302 827. Bath PM, Scutt P, Blackburn DJ, Ankolekar S, Krishnan K, Ballard C, et al. Intensive versus guideline blood pressure and lipid lowering in patients with previous stroke: main results from the pilot ‘Prevention of Decline in Cognition after Stroke Trial’ (PODCAST) randomised controlled trial. PLoS One 2017;12:e0164608. https://doi. org/10.1371/journal.pone.0164608 828. Mant J, McManus RJ, Roalfe A, Fletcher K, Taylor CJ, Martin U, et al. Different systolic blood pressure targets for people with history of stroke or transient ischaemic attack: PAST-BP (Prevention After Stroke—Blood Pressure) randomised controlled trial. BMJ 2016;352:i708. https://doi.org/10.1136/bmj.i708 829. Kolmos M, Christoffersen L, Kruuse C. Recurrent ischemic stroke—a systematic review and meta-analysis. J Stroke Cerebrovasc Dis 2021;30:105935. https://doi.org/10. 1016/j.jstrokecerebrovasdis.2021.105935 830. Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet 2020;396:413–46. https://doi.org/10.1016/s0140-6736(20)30367-6 831. Ou YN, Tan CC, Shen XN, Xu W, Hou X-H, Dong Q, et al. Blood pressure and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 209 prospective studies. Hypertension 2020;76:217–25. https://doi.org/10.1161/ hypertensionaha.120.14993 832. Abell JG, Kivimäki M, Dugravot A, Tabak AG, Fayosse A, Shipley M, et al. Association between systolic blood pressure and dementia in the Whitehall II cohort study: role of age, duration, and threshold used to define hypertension. Eur Heart J 2018;39: 3119–25. https://doi.org/10.1093/eurheartj/ehy288 833. Alpérovitch A, Blachier M, Soumaré A, Ritchie K, Dartigues J-F, Richard-Harston S, et al. Blood pressure variability and risk of dementia in an elderly cohort, the Three-City study. Alzheimers Dement 2014;10:S330–337. https://doi.org/10.1016/j. jalz.2013.05.1777 834. McGrath ER, Beiser AS, DeCarli C, Plourde KL, Vasan RS, Greenberg S, et al. Blood pressure from mid- to late life and risk of incident dementia. Neurology 2017;89: 2447–54. https://doi.org/10.1212/wnl.0000000000004741 835. Skoog I, Nilsson L, Persson G, Lernfelt B, Landahl S, Palmertz B, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996;347:1141–5. https://doi.org/ 10.1016/s0140-6736(96)90608-x 836. Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia aging study. JAMA 1995;274:1846–51. https://doi.org/10.1001/jama.1995.03530230032026 837. Gottesman RF, Albert MS, Alonso A, Coker LH, Coresh J, Davis SM, et al. Associations between midlife vascular risk factors and 25-year incident dementia in the atherosclerosis risk in Communities (ARIC) cohort. JAMA Neurol 2017;74:1246–54. https://doi. org/10.1001/jamaneurol.2017.1658 838. Levine DA, Springer MV, Brodtmann A. Blood pressure and vascular cognitive impairment. Stroke 2022;53:1104–13. https://doi.org/10.1161/strokeaha.121.036140 839. Bosch J, O’Donnell M, Swaminathan B, Lonn EM, Sharma M, Dagenais G, et al. Effects of blood pressure and lipid lowering on cognition: results from the HOPE-3 study. Neurology 2019;92:e1435–46. https://doi.org/10.1212/wnl.0000000000007174 840. Applegate WB, Pressel S, Wittes J, Luhr J, Shekelle RB, Camel GH, et al. Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. Arch Intern Med 1994;154:2154–60. https://doi.org/10.1001/archinte.1994.00420190047006 841. Williamson JD, Pajewski NM, Auchus AP, Bryan RN, Chelune G, Cheung AK, et al. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA 2019;321:553–61. https://doi.org/10.1001/jama.2018.21442 842. Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol 2008;7:683–9. https://doi.org/10.1016/s1474-4422(08)70143-1 843. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875–86. https://doi.org/10.1097/ 00004872-200305000-00011 844. White WB, Wakefield DB, Moscufo N, Guttmann CRG, Kaplan RF, Bohannon RW, et al. Effects of intensive versus standard ambulatory blood pressure control on cerebrovascular outcomes in older people (INFINITY). Circulation 2019;140:1626–35. https://doi.org/10.1161/circulationaha.119.041603 845. Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003;163:1069–75. https://doi.org/10.1001/archinte.163.9.1069 846. Peters R, Yasar S, Anderson CS, Andrews S, Antikainen R, Arima H, et al. Investigation of antihypertensive class, dementia, and cognitive decline: a meta-analysis. Neurology 2020;94:e267–81. https://doi.org/10.1212/wnl.0000000000008732 847. Yang W, Luo H, Ma Y, Si S, Zhao H. Effects of antihypertensive drugs on cognitive function in elderly patients with hypertension: a review. Aging Dis 2021;12:841–51. https:// doi.org/10.14336/ad.2020.1111 848. Iseli R, Nguyen VTV, Sharmin S, Reijnierse EM, Lim WK, Maier AB, et al. Orthostatic hypotension and cognition in older adults: a systematic review and meta-analysis. Exp Gerontol 2019;120:40–9. https://doi.org/10.1016/j.exger.2019.02.017 849. Ernst ME, Ryan J, Chowdhury EK, Margolis KL, Beilin LJ, Reid CM, et al. Long-term blood pressure variability and risk of cognitive decline and dementia among older adults. J Am Heart Assoc 2021;10:e019613. https://doi.org/10.1161/jaha.120.019613 850. Nakamura K, Stefanescu Schmidt A. Treatment of hypertension in coarctation of the aorta. Curr Treat Options Cardiovasc Med 2016;18:40. https://doi.org/10.1007/s11936- 016-0462-x 851. Dijkema EJ, Leiner T, Grotenhuis HB. Diagnosis, imaging and clinical management of aortic coarctation. Heart 2017;103:1148–55. https://doi.org/10.1136/heartjnl-2017- 311173 852. Panzer J, Bové T, Vandekerckhove K, De Wolf D. Hypertension after coarctation repair-a systematic review. Transl Pediatr 2022;11:270–9. https://doi.org/10.21037/ tp-21-418 853. Schaefer BM, Lewin MB, Stout KK, Gill E, Prueitt A, Byers P H, et al. The bicuspid aortic valve: an integrated phenotypic classification of leaflet morphology and aortic root shape. Heart 2008;94:1634–8. https://doi.org/10.1136/hrt.2007.132092 854. Wang J, Deng W, Lv Q, Li Y, Liu T, Xie M, et al. Aortic dilatation in patients with bicuspid aortic valve. Front Physiol 2021;12:615175. https://doi.org/10.3389/fphys.2021. 615175 855. Davies RR, Kaple RK, Mandapati D, Gallo A, Botta DM, Elefteriades JA, et al. Natural history of ascending aortic aneurysms in the setting of an unreplaced bicuspid aortic valve. Ann Thorac Surg 2007;83:1338–44. https://doi.org/10.1016/j.athoracsur.2006. 10.074 856. Lindman BR, Otto CM. Time to treat hypertension in patients with aortic stenosis. Circulation 2013;128:1281–3. https://doi.org/10.1161/circulationaha.113.005275 857. Erbel R, Aboyans V, Boileau C, Bossone E, Di Bartolomeo R, Eggebrecht H, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J 2014;35:2873–926. https://doi.org/10.1093/ eurheartj/ehu281 858. Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan’s syndrome. N Engl J Med 1994;330:1335–41. https://doi.org/10.1056/nejm199405123301902 859. Groenink M, den Hartog AW, Franken R, Radonic T, de Waard V, Timmermans J, et al. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. Eur Heart J 2013;34:3491–500. https://doi.org/10.1093/ eurheartj/eht334 860. Pitcher A, Spata E, Emberson J, Davies K, Halls H, Holland L, et al. Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials. Lancet 2022;400:822–31. https://doi.org/10.1016/s0140-6736(22)01534-3 861. Mazzolai L, Rodriguez-Palomares JF, Teixido-Tura G, Lanzi S, Boc V, Bossone E, et al. 2024 ESC Guidelines for the management peripheral arterial and aortic diseases. Eur Heart J 2024;45:3538–700. https://doi.org/10.1093/eurheartj/ehae179 862. Rechel B, Mladovsky P, Ingleby D, Mackenbach JP, McKee M. Migration and health in an increasingly diverse Europe. Lancet 2013;381:1235–45. https://doi.org/10.1016/s0140- 6736(12)62086-8 863. Modesti PA, Reboldi G, Cappuccio FP, Agyemang C, Remuzzi G, Rapi S, et al. Panethnic differences in blood pressure in Europe: a systematic review and meta-analysis. PLoS One 2016;11:e0147601. https://doi.org/10.1371/journal.pone.0147601 864. Whelton PK, Einhorn PT, Muntner P, Appel LJ, Cushman WC, Diez Roux AV, et al. Research needs to improve hypertension treatment and control in African Americans. Hypertension 2016;68:1066–72. https://doi.org/10.1161/hypertensionaha.116.07905 865. Kaufman JS, Cooper RS, McGee DL. Socioeconomic status and health in blacks and whites: the problem of residual confounding and the resiliency of race. Epidemiology 1997;8:621–8. 866. Agyemang C, van Oeffelen AA, Norredam M, Kappelle LJ, Klijn CJM, Bots ML, et al. Socioeconomic inequalities in stroke incidence among migrant groups: analysis of nationwide data. Stroke 2014;45:2397–403. https://doi.org/10.1161/strokeaha. 114.005505 Downloaded from academic.oup.com/eurheartj/article/45/38/3912/7741010 by guest on 07 October 2026